Single-Patient Trials May Benefit Postmarketing Surveillance, Exec Tells FDA
Executive Summary
Postmarketing surveillance could be bolstered by aggregate safety and efficacy data collected from standardized single-patient trials, Opt-e-scrip Scientific Affairs President Donald Reitberg said